Latest

3 stories

Hide weekly roundups

Wednesday, August 5

Quarterly updateXencor, Inc.XMAB819 XMAB942

Xencor reports Q2 2026 results, sets ESMO date for XmAb819 kidney cancer data

Xencor confirmed a 2027 registration-enabling study plan for XmAb819 in kidney cancer, a 2H27 primary endpoint for XmAb942 in ulcerative colitis, and new Alexion settlement terms.

SEC filing

Wednesday, July 29

Partnershipravulizumab Xencor, Inc.

Xencor to receive $105 million from Alexion to settle Ultomiris royalty dispute

The payment resolves a dispute over U.S. royalties on Ultomiris, with Alexion ending U.S. royalty obligations while ex-U.S. royalties continue unchanged.

SEC filing

Monday, July 20

Xencor's Phase 1 trial of XmAb412 in healthy volunteers is recruiting

Trial updateXencor, Inc.